Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Searle NSAID-induced ulcer risk consumer awareness campaign kicks off.

This article was originally published in The Tan Sheet

Executive Summary

SEARLE NSAID GASTRIC ULCER RISK CONSUMER AWARENESS CAMPAIGN was unveiled March 19 in conjunction with the American Gastro- enterological Association. REDUCE, the Risk Education to Decrease Ulcer Complications and their Effects from NSAIDs, aims to increase public awareness of the "incidence of stomach ulcers and other serious gastrointestinal (GI) complications caused by common prescription and over-the-counter pain relievers known as non-steroidal anti-inflammatory drugs (NSAIDs)," Searle said. The company markets the Rx drug Arthrotec (diclofenac 50 or 75 mg/misoprostol 200 mcg) for pain relief and treatment of NSAID-induced ulcers.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088242

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel